Archive for 'Psych Drugs'

HomePsych Drugs

Posted by:

Citicoline preserves memory in dementia

August 1, 2012 (Vancouver, British Columbia) — The dietary supplement citicoline, which is sold over the counter in 70 different countries, including the United States, appears to help memory in patients with vascular mild cognitive impairment (VaMCI) and may hinder cognitive deterioration, new research suggests.

Preliminary results from a longitudinal study presented here at the Alzheimer’s Association International Conference (AAIC) 2012 showed that at 9 months, there was a significant difference in Mini–Mental State Examination (MMSE) scores ...

Continue Reading →
7
AUG
0

Categories: ADD/ADHD, Alzheimer's and other Dementias, Mental Focus/Brain Fog, Psych Drugs, Wellness

Metformin safest for prediabetes, diabites, and now mental disorders

Posted by:

Metformin for Treatment of Antipsychotic-Induced Amenorrhea and Weight Gain in Women With First-Episode Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Study

Objective:  Data on the treatment of antipsychotic-induced amenorrhea, particularly when occurring with weight gain, are limited. The authors investigated the efficacy and safety of metformin in the treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia.

Method:  Eighty-four women (ages 18–40 years) with first-episode schizophrenia who suffered from amenorrhea during antipsychotic treatment were randomly assigned, in a double-blind study design, ...

Continue Reading →
6
AUG
0

Categories: ADD/ADHD, Allergies, Diabetes/Prediabetes, Mental Focus/Brain Fog, Psych Drugs, Wellness

Nutritional Deficiencies and Alzheimer’s By David Reinhardt, Ph.D., ABMP

Posted by:

The Study
Medical Food Linked to Memory Improvement in Mild Alzheimer’s
Administration of a medical food designed to improve synaptic dysfunction is associated with continuous memory improvement in patients with mild Alzheimer’s disease (AD), new research shows.
Presented here at the Alzheimer’s Association International Conference (AAIC) 2012, results from an open-label extension (OLE) trial of a medical nutrition product (Souvenaid, Nutricia/Danone) showed that memory performance continued to improve in drug-naïve patients with mild AD for up to 48 weeks.
At ...

Continue Reading →
1
AUG
0

Categories: Alzheimer's and other Dementias, Anti-Aging, Psych Drugs, Wellness

Nutritional Needs and Health By David Reinhardt, Ph.D. ABMP

Posted by:

Nutritional deficiencies have been linked to most psychiatric “illnesses”, including depression, ADHD, schizophrenia, bipolar disorders, and even personality disorders and autism.  Treatment of these disorders with nutrients has limited effectiveness, although in the case of depression and schizophrenia a large body of evidence supports a curative role.
Adequate nutrition has its biggest impact on maintaining health and reducing the occurrence of psychiatric and other disorders.
The  Study
Do Dietary Supplements Improve Micronutrient Sufficiency in Children and Adolescents?
To examine if ...

Continue Reading →
1
AUG
0

Categories: ADD/ADHD, Alzheimer's and other Dementias, Anti-Aging, Depression, Diabetes/Prediabetes, Psych Drugs, Wellness

Another Triumph for Big Pharma by David Reinhardt, Ph.D., ABMP

Posted by:

“On July 26 the FDA approved a patented synthetic version of the Omega 3 fatty acid EPA, (Vascepa, by Amarin) for the treatment of hypertriglyceridemia.  It should now become the market’s second omega-3 polyunsaturated fatty acid (PUFA) preparation available only by prescription.  Vascepa is a purified marine-oil preparation of consisting of “not less than 96%” EPA, Amarin notes in its literature.  It doesn’t contain significant amounts of the other active omega-3 PUFA,  DHA, that is a major component of nonprescription ...

Continue Reading →
1
AUG
0

Categories: Allergies, Alzheimer's and other Dementias, Anti-Aging, Anxiety, Autoimmune Diseases, Depression, Diabetes/Prediabetes, Hypertension, Immunity/Colds/Flu, Psych Drugs, Thyroid Disorders

Relabeling the Medications We Call Antidepressants by David Antonuccio, Ph.D and David Healy M.D.

Posted by:

Abstract
This paper raises the question about whether the data on the medications we call antidepressants justify the label of antidepressant. The authors argue that a true antidepressant should be clearly superior to placebo, should offer a risk/benefit balance that exceeds that of alternative treatments, should not increase suicidality, should not increase anxiety and agitation, should not interfere with sexual functioning, and should not increase depression chronicity. Unfortunately, these medications appear to fall short on all of these dimensions. Many ...

Continue Reading →
1
AUG
0

Categories: Depression, Psych Drugs